Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72

Benzinga · 1d ago
Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $61 to $72.